Understanding DLBCL: A Complete Guide

What is Diffuse Large B-Cell Lymphoma (DLBCL)?

Diffuse Large B-Cell Lymphoma (DLBCL) is the most common type of Non-Hodgkin Lymphoma, accounting for approximately 30–40% of all NHL cases worldwide. It develops when B lymphocytes (B cells)—a type of white blood cell responsible for producing antibodies—grow uncontrollably and form cancerous tumors within the lymphatic system. The word "Diffuse" refers to the scattered pattern of cancer cells seen under a microscope, while "Large B-Cell" describes the appearance and origin of the abnormal lymphocytes.

Unlike slow-growing (indolent) lymphomas, DLBCL is considered an aggressive lymphoma, meaning it can grow and spread quickly. However, its rapid growth also makes it more responsive to modern treatments, and many patients can achieve complete remission when therapy is started promptly.

Although DLBCL usually begins in the lymph nodes, it can also develop in organs outside the lymphatic system, known as extranodal disease. Common extranodal sites include the stomach, intestines, skin, bones, brain, liver, thyroid, and testes.

Understanding the Lymphatic System

To understand DLBCL, it is helpful to know how the lymphatic system works.

The lymphatic system is a vital part of the body's immune defense. It protects against infections and helps maintain fluid balance.

It consists of:

• Lymph nodes
• Bone marrow
• Spleen
• Thymus
• Tonsils
• Lymphatic vessels

Within this system are B lymphocytes, which produce antibodies to fight bacteria, viruses, and other harmful microorganisms.

Normally, B cells grow, mature, and die in a controlled manner. In DLBCL, genetic changes cause these cells to multiply uncontrollably without dying, leading to the formation of lymphoma.

As the disease progresses, abnormal B cells accumulate in lymph nodes or other organs, interfering with normal immune function.

Types of DLBCL

Although DLBCL is grouped under one disease name, it includes several biological subtypes. Identifying the subtype helps hematologists choose the most appropriate treatment strategy.

Germinal Center B-cell (GCB) DLBCL

This is the most common subtype.

It develops from B cells originating in the germinal center of lymph nodes and generally responds well to standard immunochemotherapy.

Patients with GCB DLBCL often have a more favorable prognosis than some other subtypes.

Activated B-cell (ABC) DLBCL

ABC DLBCL arises from B cells that have progressed beyond the germinal center stage.

This subtype tends to be more aggressive and may require more intensive treatment or enrollment in clinical trials if standard therapy is unsuccessful.

Primary Mediastinal Large B-Cell Lymphoma

This rare subtype typically affects younger adults, particularly women.

It begins in the mediastinum (the area between the lungs) and may cause symptoms such as:

• Chest pain
• Persistent cough
• Shortness of breath
• Swelling of the face or neck

With appropriate treatment, many patients achieve excellent outcomes.

Double-Hit and Triple-Hit Lymphomas

These aggressive forms of DLBCL are characterized by specific genetic abnormalities involving genes such as MYC, BCL2, and BCL6.

Compared to standard DLBCL, these lymphomas often require more intensive treatment approaches and careful monitoring by experienced hematologists.

What are the Causes of DLBCL?

The exact cause of DLBCL remains unknown. However, researchers believe that multiple genetic and environmental factors contribute to the development of the disease.

In most cases, DLBCL is not inherited and cannot be prevented.

Risk Factors for DLBCL

Certain factors may increase the likelihood of developing DLBCL.

These include:

• Age over 60 years
• Weakened immune system
• HIV infection
• Epstein-Barr virus (EBV) infection
• Hepatitis C infection
• Autoimmune disorders
• Previous chemotherapy or radiation therapy
• Organ transplantation
• Long-term use of immunosuppressive medications
• Family history of lymphoma (in some cases)

Having one or more risk factors does not necessarily mean a person will develop DLBCL, and many patients have no identifiable risk factors.

Common Symptoms of DLBCL

Symptoms vary depending on where the lymphoma develops and how far it has spread.

The most common symptom is a painless swollen lymph node, usually in the neck, armpit, or groin.

Other symptoms may include:

• Persistent fever without infection
• Night sweats
• Unexplained weight loss
• Severe fatigue
• Loss of appetite
• Persistent cough
• Chest discomfort
• Shortness of breath
• Abdominal pain or swelling
• Back pain
• Bone pain
• Itching
• Frequent infections

The combination of fever, night sweats, and unexplained weight loss is known as "B symptoms," which help doctors determine the stage and prognosis of the disease.

Patients with lymphoma affecting organs outside the lymph nodes may also experience organ-specific symptoms. For example:

• Brain: Headaches, seizures, weakness, or confusion
• Stomach: Indigestion, abdominal pain, nausea, or gastrointestinal bleeding
• Skin: Raised nodules or persistent skin lesions
• Bones: Localized pain or fractures
• Testes: Swelling or discomfort

Any persistent or unexplained symptoms should be evaluated by a hematologist promptly.

When Should You See a Hematologist?

Many early symptoms of DLBCL can resemble common infections, making diagnosis challenging. However, you should seek medical attention if you notice:

• Enlarged lymph nodes lasting more than two weeks
• Fever without a known cause
• Night sweats that soak clothing or bedding
• Unexplained weight loss
• Persistent fatigue
• Swollen lymph nodes that continue to enlarge
• Persistent abdominal swelling or pain
• Ongoing cough or breathing difficulty without improvement

Early diagnosis allows treatment to begin before the disease progresses further and can significantly improve outcomes.

How is DLBCL Diagnosed?

An accurate diagnosis is essential because treatment decisions depend on the lymphoma subtype, stage, and molecular characteristics.

Medical History and Physical Examination

The hematologist will review your symptoms, medical history, and family history while examining enlarged lymph nodes, the liver, spleen, and other areas of concern.

Blood Tests

Routine blood tests help assess overall health and organ function.

These may include:

• Complete Blood Count (CBC)
• Lactate Dehydrogenase (LDH)
• Liver Function Tests
• Kidney Function Tests
• Uric Acid
• Viral Screening (HIV, Hepatitis B, Hepatitis C)
• ESR and CRP (where indicated)

Lymph Node Biopsy

A lymph node biopsy is the gold standard for diagnosing DLBCL.

During this procedure, all or part of an enlarged lymph node is removed and examined under a microscope.

The biopsy confirms whether lymphoma is present and identifies the specific subtype.

Immunohistochemistry (IHC)

Immunohistochemistry is performed on biopsy samples to identify proteins present on lymphoma cells.

It helps distinguish DLBCL from other lymphomas and guides treatment planning.

Flow Cytometry

Flow cytometry analyzes lymphoma cells using specialized laboratory techniques.

It helps determine the immunophenotype of abnormal B cells and supports accurate diagnosis.

PET-CT Scan

A PET-CT scan is one of the most important investigations for DLBCL.

It is used to:

• Determine disease stage
• Identify all areas affected by lymphoma
• Evaluate treatment response
• Detect relapse during follow-up

PET-CT is considered the preferred imaging method for staging and monitoring DLBCL.

CT Scan or MRI

CT and MRI scans provide additional information about the size and location of tumors, especially when specific organs are involved.

Bone Marrow Biopsy

A bone marrow biopsy may be recommended to determine whether the lymphoma has spread to the bone marrow.

This information is important for staging and treatment planning.

Molecular and Genetic Testing

Advanced laboratory tests such as FISH (Fluorescence In Situ Hybridization) and cytogenetic analysis help detect genetic abnormalities, including double-hit and triple-hit lymphomas.

These tests guide risk assessment and treatment selection.

Estimated Diagnostic Investigation Costs in India

Investigation	Estimated Cost (USD)
Hematologist Consultation	$30–40
Blood Investigations	$50–150
Lymph Node Biopsy	$200–300
Immunohistochemistry (IHC)	$150–350
PET-CT Scan	$300–500
CT Scan	$120–200
Bone Marrow Biopsy	$150–400
Molecular Testings	$300–700

These costs are approximate and may vary depending on the hospital, city, and the patient's specific diagnostic requirements.

Staging of DLBCL

Once DLBCL is confirmed, doctors determine how far the lymphoma has spread using the Ann Arbor Staging System.

Stage I

The lymphoma is limited to a single lymph node region or one organ outside the lymphatic system.

Stage II

The lymphoma involves two or more lymph node regions on the same side of the diaphragm or one nearby organ.

Stage III

The lymphoma is present in lymph node regions on both sides of the diaphragm and may involve the spleen.

Stage IV

The lymphoma has spread beyond the lymphatic system to organs such as the liver, lungs, bone marrow, or central nervous system.

In addition to staging, hematologists often use the International Prognostic Index (IPI) to assess risk and help guide treatment decisions based on factors such as age, disease stage, LDH level, overall health, and the number of extranodal sites involved.

How is DLBCL Treated?

Treatment usually begins soon after the diagnosis is confirmed because DLBCL is a fast-growing lymphoma. Before starting therapy, your hematologist will review:

• Stage of the disease
• PET-CT scan findings
• Biopsy and molecular test results
• International Prognostic Index (IPI)
• Age and overall health
• Heart, liver, and kidney function
• Previous medical conditions

The treatment plan is discussed by a multidisciplinary team that may include hematologists, medical oncologists, radiation oncologists, radiologists, pathologists, and transplant specialists.

Chemotherapy for DLBCL

Chemotherapy remains the cornerstone of DLBCL treatment. It destroys rapidly growing lymphoma cells throughout the body.

The exact chemotherapy regimen depends on the patient's condition and disease characteristics.

Immunotherapy

Immunotherapy has transformed the treatment of many blood cancers, including DLBCL.

Instead of directly killing cancer cells, immunotherapy helps the body's immune system recognize and destroy lymphoma cells.

Rituximab

Rituximab is a monoclonal antibody that targets the CD20 protein found on B cells.

It has significantly improved survival rates when combined with chemotherapy.

Benefits

• Improves cure rates
• Reduces relapse risk
• Widely used worldwide
• Well tolerated by most patients

Bispecific Antibodies

Newer immunotherapies known as bispecific antibodies help immune cells attack lymphoma cells by connecting T cells directly to cancer cells.

These therapies are particularly promising for patients whose lymphoma has relapsed after standard treatment and are becoming increasingly available in specialized centers.

Targeted Therapy

Targeted therapies focus on specific molecules involved in the growth and survival of lymphoma cells, offering a more precise approach than traditional chemotherapy.

Stem Cell Transplantation

Stem cell transplantation is recommended for some patients whose lymphoma returns after initial treatment or does not respond adequately to first-line therapy.

Autologous Stem Cell Transplant (ASCT)

In an autologous transplant, the patient's own healthy stem cells are collected before high-dose chemotherapy.

After chemotherapy destroys the lymphoma cells, the stored stem cells are infused back into the body to restore bone marrow function.

Who May Benefit?

• Patients with relapsed DLBCL
• Patients responding to salvage chemotherapy
• Fit individuals eligible for high-dose treatment

Advantages

• Potential for long-term remission
• Standard treatment for eligible relapsed patients
• Uses the patient's own cells, reducing the risk of graft-versus-host disease

Allogeneic Stem Cell Transplant

An allogeneic transplant uses stem cells from a compatible donor.

It may be considered for selected patients with high-risk or multiple relapses, particularly when other treatment options have been exhausted.

Because it carries a higher risk of complications, careful patient selection is essential.

CAR T-Cell Therapy

CAR T-cell therapy represents one of the most significant advances in treating relapsed or refractory DLBCL.

This personalized treatment involves modifying the patient's own T cells in a laboratory so they can recognize and destroy lymphoma cells more effectively.

How Does CAR T-Cell Therapy Work in DLBCL?

1. T cells are collected from the patient.
2. The cells are genetically modified to recognize cancer cells.
3. Millions of CAR T cells are produced in the laboratory.
4. The modified cells are infused back into the patient.
5. The CAR T cells seek out and destroy lymphoma cells.

When Is CAR T-Cell Therapy Recommended?

• DLBCL that has relapsed after multiple treatments
• Patients not responding to chemotherapy
• Patients unsuitable for stem cell transplantation
• Selected high-risk cases based on specialist evaluation

Benefits

• Personalized treatment
• High response rates in appropriate patients
• Potential for durable remission
• Effective even after previous therapies have failed

Because CAR T-cell therapy can cause serious side effects such as cytokine release syndrome (CRS) and neurological complications, it should only be performed at experienced centers with specialized monitoring.

Radiation Therapy

Radiation therapy is not required for every patient with DLBCL, but it plays an important role in selected situations.

It may be recommended for:

• Localized disease
• Bulky tumors
• Residual lymphoma after chemotherapy
• Symptom relief in specific cases

Modern techniques such as IMRT and IGRT allow precise targeting of lymphoma while minimizing radiation exposure to healthy tissues.

What are the Possible Side Effects of Treatment?

The side effects of DLBCL treatment vary depending on the therapies used.

Chemotherapy

Common side effects include:

• Fatigue
• Hair loss
• Nausea and vomiting
• Mouth sores
• Low blood counts
• Increased infection risk

Immunotherapy

Possible side effects include:

• Infusion reactions
• Fever
• Chills
• Skin rash
• Fatigue

Stem Cell Transplant

Recovery after transplantation may involve:

• Temporary low blood counts
• Increased infection risk
• Fatigue
• Need for close medical monitoring

CAR T-Cell Therapy

Potential complications include:

• Cytokine Release Syndrome (CRS)
• Neurological side effects
• Fever
• Low blood pressure
• Increased susceptibility to infections

Most side effects can be managed effectively with early recognition and supportive care.

Follow-Up Care after Treatment

Even after successful treatment, regular follow-up is essential to monitor recovery and detect any signs of recurrence.

Follow-up visits may include:

• Physical examinations
• Blood tests
• PET-CT or CT scans when indicated
• Assessment of long-term treatment effects
• Monitoring of heart and other organ functions in selected patients

Most patients are monitored more frequently during the first two years, when the risk of relapse is highest.

DLBCL Treatment Cost in India

One of the major advantages of seeking DLBCL treatment in India is affordability. Patients receive high-quality care from experienced hematologists using internationally accepted treatment protocols while benefiting from considerably lower treatment costs than in countries such as the United States, the United Kingdom, Australia, or many European nations.

Estimated DLBCL Treatment Costs in India

Treatment	Estimated Cost (USD)
Targeted Therapy	$2,500–6,000
Radiation Therapy	$3,500–6,500
Hospital Stay (Per Day)	$200–300
Autologous Stem Cell Transplant	$14,000–16,000
Allogeneic Stem Cell Transplant	$25,000–35,000
CAR T-Cell Therapy	$45,000–60,000

Note: These are approximate costs. The final treatment cost depends on the patient's diagnosis, treatment plan, hospital, city, medications, and duration of care.

Factors That Affect the Cost of DLBCL Treatment

The overall cost of treatment may vary depending on several factors, including:

• Stage of the lymphoma
• Biological subtype of DLBCL
• Patient's age and overall health
• Number of chemotherapy cycles required
• Need for immunotherapy or targeted therapy
• Requirement for radiation therapy
• Stem cell transplantation, if indicated
• Duration of hospitalization
• Intensive care requirements (if any)
• Diagnostic and follow-up investigations
• Management of treatment-related complications

Discussing the complete treatment plan with your hematologist before starting therapy helps you understand the expected costs and prepare accordingly.

Can DLBCL Be Cured?

Yes. DLBCL is considered one of the most curable aggressive blood cancers, especially when diagnosed early and treated promptly.

Many patients achieve complete remission with first-line treatment, while others who experience relapse may still respond well to advanced therapies such as stem cell transplantation or CAR T-cell therapy.

The likelihood of cure depends on:

• Disease stage
• Age
• Overall health
• Tumor biology
• Response to initial treatment
• Timely diagnosis
• Availability of advanced treatment options

Following the recommended treatment plan and attending regular follow-up appointments play an important role in achieving the best possible outcome.

Recovery After DLBCL Treatment

Recovery is different for every patient. Some individuals regain their normal routine within a few months, while others may require more time, particularly after stem cell transplantation or intensive chemotherapy.

During Recovery

Patients are encouraged to:

• Eat a balanced and protein-rich diet
• Stay physically active with light exercise as advised
• Drink plenty of fluids
• Get adequate rest
• Avoid tobacco and excessive alcohol
• Practice good hygiene to reduce infection risk
• Follow medication instructions carefully
• Attend all scheduled follow-up visits

Regular monitoring helps ensure early detection of any recurrence or long-term treatment-related effects.

Lifestyle Tips for DLBCL Patients

Adopting healthy lifestyle habits can support recovery and improve overall well-being.

Healthy Diet

Choose foods rich in:

• Lean proteins
• Fresh fruits
• Vegetables
• Whole grains
• Healthy fats

If you have difficulty eating during treatment, consult a dietitian for personalized nutritional advice.

Physical Activity

Light to moderate exercise, such as walking or stretching, may help improve energy levels, reduce fatigue, and enhance emotional well-being. Always follow your healthcare team's recommendations.

Emotional Well-Being

A cancer diagnosis can affect emotional health. Counseling, support groups, and spending time with family and friends can help reduce stress and improve quality of life during treatment and recovery.

Why International Patients Choose India for DLBCL Treatment

India has become one of the leading destinations for the treatment of blood cancers because it combines experienced specialists, advanced medical technology, and affordable care.

International patients choose India because of:

• Highly experienced hematologists and hemato-oncologists
• Advanced diagnostic laboratories
• Modern chemotherapy and immunotherapy facilities
• Expertise in stem cell transplantation
• Availability of CAR T-cell therapy at selected centers
• JCI and NABH-accredited hospitals
• Multidisciplinary cancer care teams
• Short waiting times
• Affordable treatment costs
• Dedicated international patient support services

Patients from the Middle East, Africa, Central Asia, South Asia, and many other regions travel to India for comprehensive lymphoma care.

Why Choose Dr. Rahul Bhargava for DLBCL Treatment?

Choosing the Right Hematologist is one of the most important decisions for patients diagnosed with DLBCL.

Dr. Rahul Bhargava is one of India's leading hematologists and bone marrow transplant specialists, with extensive experience in treating lymphoma, leukemia, multiple myeloma, aplastic anemia, and other complex blood disorders.

Patients choose Dr. Rahul Bhargava because of his:

• Extensive experience in hematology and hemato-oncology
• Expertise in treating Diffuse Large B-Cell Lymphoma (DLBCL)
• Specialized knowledge in autologous and allogeneic stem cell transplantation
• Personalized treatment plans based on each patient's condition
• Evidence-based treatment approach following international guidelines
• Multidisciplinary collaboration with experienced cancer specialists
• Commitment to patient education and compassionate care
• Experience in managing international patients from across the world

Every patient receives an individualized treatment plan designed to achieve the best possible clinical outcome while maintaining quality of life.

Final Thought

Diffuse Large B-Cell Lymphoma (DLBCL) is an aggressive but highly treatable form of Non-Hodgkin Lymphoma. Early diagnosis, accurate staging, and timely treatment using modern therapies such as chemotherapy, immunotherapy, targeted therapy, stem cell transplantation, and CAR T-cell therapy have significantly improved patient outcomes.

India has earned a strong reputation for delivering high-quality hematology care through experienced specialists, advanced treatment facilities, internationally accredited hospitals, and affordable treatment options. For international patients seeking expert care, India offers comprehensive support throughout the treatment journey.

If you or a loved one has been diagnosed with DLBCL, consulting an experienced hematologist is the first step toward receiving the most appropriate treatment. Dr. Rahul Bhargava combines extensive clinical experience, expertise in lymphoma management and stem cell transplantation, and a patient-centered approach to provide personalized care for individuals with DLBCL and other blood cancers.

Early intervention and the right treatment strategy can make a significant difference. Seeking expert guidance as soon as possible can improve outcomes and help patients move confidently toward recovery.